Results 81 to 90 of about 1,917,753 (288)

Comparison of New York and San Francisco Hospital Records [PDF]

open access: yes
birth weight; economics of health; perinatal health ...
Tayatat Kanjanapipatkul
core  

Despite Regulatory Changes, Hospitals Cautious in Helping Physicians Purchase Electronic Medical Records [PDF]

open access: yes, 2008
Examines hospitals' strategies to aid physicians' adoption of electronic medical records (EMRs) following regulatory changes facilitating hospital-subsidized EMRs.
Genna R. Cohen, Joy M. Grossman
core  

Screening for lung cancer: A systematic review of overdiagnosis and its implications

open access: yesMolecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz   +12 more
wiley   +1 more source

A Simple Free-Text-like Method for Extracting Semi-Structured Data from Electronic Health Records: Exemplified in Prediction of In-Hospital Mortality [PDF]

open access: gold, 2021
Eyal Klang   +8 more
openalex   +1 more source

Multimodality management of soft tissue sarcomas [PDF]

open access: yes, 1990
Soft tissue sarcomas are a heterogeneous group of malignant tumours arising from connective tissues of mesenchymal origin. By definition sarcomas arising from bone or cartilage are excluded though they have much in common in their behaviour as well as in
Brincat, Stephen
core  

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy